Aimmune Therapeutics Inc (NASDAQ:AIMT) – Research analysts at Wedbush reduced their FY2019 EPS estimates for shares of Aimmune Therapeutics in a research note issued to investors on Tuesday, March 19th, Zacks Investment Research reports. Wedbush analyst L. Moussatos now anticipates that the biotechnology company will earn ($3.66) per share for the year, down from their previous estimate of ($3.63). Wedbush has a “Buy” rating and a $79.00 price objective on the stock. Wedbush also issued estimates for Aimmune Therapeutics’ Q4 2019 earnings at ($0.95) EPS, Q1 2020 earnings at ($0.89) EPS, Q2 2020 earnings at ($0.85) EPS, Q3 2020 earnings at ($0.80) EPS, Q4 2020 earnings at ($0.53) EPS, FY2020 earnings at ($3.07) EPS, FY2021 earnings at ($0.33) EPS, FY2022 earnings at $3.95 EPS and FY2023 earnings at $11.14 EPS.
A number of other equities research analysts have also recently issued reports on the stock. BidaskClub raised shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, January 11th. Zacks Investment Research downgraded Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, January 14th. ValuEngine downgraded Aimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, January 2nd. Cantor Fitzgerald set a $45.00 price target on Aimmune Therapeutics and gave the company a “buy” rating in a report on Thursday, February 28th. Finally, Goldman Sachs Group set a $36.00 price objective on Aimmune Therapeutics and gave the company a “hold” rating in a research note on Thursday, December 20th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $47.13.
A number of hedge funds and other institutional investors have recently modified their holdings of AIMT. Alliancebernstein L.P. lifted its stake in Aimmune Therapeutics by 25.7% in the third quarter. Alliancebernstein L.P. now owns 1,915,689 shares of the biotechnology company’s stock valued at $52,260,000 after buying an additional 391,818 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Aimmune Therapeutics by 223.4% in the fourth quarter. Bank of New York Mellon Corp now owns 553,206 shares of the biotechnology company’s stock valued at $13,233,000 after buying an additional 382,154 shares during the last quarter. BlackRock Inc. lifted its stake in Aimmune Therapeutics by 9.3% in the third quarter. BlackRock Inc. now owns 3,982,580 shares of the biotechnology company’s stock valued at $108,644,000 after buying an additional 338,740 shares during the last quarter. Emerald Advisers LLC raised its stake in shares of Aimmune Therapeutics by 52.4% during the fourth quarter. Emerald Advisers LLC now owns 741,746 shares of the biotechnology company’s stock worth $17,743,000 after purchasing an additional 255,080 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Aimmune Therapeutics during the fourth quarter worth approximately $6,035,000. Institutional investors own 73.85% of the company’s stock.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
Featured Article: Risk Tolerance and Your Investment Decisions
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.